Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

bioAffinity Technologies Inc

BIAF ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Medical Equipment, Supplies & Distribution ·

USA Micro Cap Analyst: N/A

Last Close

$5.64

▼ -8.44%

Market Cap $6.58M · Vol 3.38M

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$6.58M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

19.29

Momentum

Beta

-1.27

vs Market

52W High

$80.70

93.01% below

52W Low

$4.56

23.68% above

Volume

3.38M

Avg 828.75K

P/B

0.73

Price-to-book

ROE

N/A

Return on equity

Free Float

99.16%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, bioAffinity Technologies Inc (BIAF) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does BIAF pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-8.22%

-36.84%

-52.34%

-90.41%

YTD

-68.14%

-87.67%

-99.04%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$6.16M
Net Income	$-14,909,750.00
Revenue Growth (YoY)	+18.99%
Gross Margin	23.21%
Operating Margin	-171.58%
Net Profit Margin	-241.96%
ROE	N/A
ROA · ROIC	-170.14% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	0.33
P/B	0.73
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	1.17M

Technical Indicators

50-Day SMA	$7.42
200-Day SMA	$20.47
RSI (14)	19.29
Beta	-1.27
52-Week High	$80.70
52-Week Low	$4.56

Volume Today	3.38M
Avg Daily Volume (30D)	828.75K
Relative Volume	4.08x
Volatility (10D)	61.73
Volatility (30D)	311.42
Free Float	99.16%

Analyst Consensus

N/A

Current Price $5.64

Mean Target N/A

52W Low$4.56 52W High$80.70

Current

Target

$4.56 $80.70

Current Analyst target

· 0 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00H69JDY0

ISINUS09076W4069

CountryUSA

Sub-IndustryLaboratory Diagnostic & Testing Substances

Earnings DateN/A

TypeStocks

Instrument TypeADR American Depositary Receipt

Similar Halal Stocks

GH Guardant Health, Inc. -1.65% BIM.PA Biomerieux SA -0.43% TXG 10x Genomics, Inc. +1.55% CAI Caris Life Sciences, Inc. +1.48% LNTH Lantheus Holdings, Inc. -0.06%

Company Profile

bioAffinity Technologies, Inc. is a biotechnology company focused on the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. It develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.